Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNC0165-1562 First Human Dose in Obesity
NCT02568306Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Oct 2015
- Primary completion
- Feb 2017
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity comparing NNC0165-1562 with Placebo (2 arms). Primary endpoint: Treatment Emergent Adverse Events. Started Oct 2015; status: completed.
02
Drugs
NNC0165-1562
03
Conditions
obesity
Beyond the preview
Go deeper on NCT02568306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02568306.